Abstract
Question
1. What are the most important diagnostic considerations in reporting progressive glioblastoma?
Target population
These recommendations apply to adults with progressive glioblastoma
Recommendations
Level III
For patients who undergo biopsy or neurosurgical resection at the time of radiologic or clinical progression, it is recommended that the pathologist report the presence and extent of progressive neoplasm as well as the presence and extent of necrosis within the pathologic material examined.
Furthermore, to ensure the proper interpretation of progressive glioblastoma, it is recommended that the pathologist take into account the patient’s previous diagnosis and treatment, as well as the current clinical and neuroimaging features that have led to a second biopsy or resection.
Question
2. What techniques and ancillary studies are most useful in separating malignant progression from treatment effect?
Target population
These recommendations apply to adults with progressive glioblastoma
Recommendations
Level III
In the setting of prior radiation and chemotherapy, it is recommended to adhere to strict histologic criteria for microvascular proliferation and necrosis in order to establish a diagnosis of a glioblastoma.
Immunohistochemistry and genetic studies are selectively recommended for distinguishing neoplastic cells from atypical reactive cells in progressive glioblastoma.
Similar content being viewed by others
References
Darefsky AS, King JT Jr, Dubrow R (2012) Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of surveillance, epidemiology, and end results registries. Cancer 118(8):2163–2172
Koshy M, Villano JL, Dolecek TA et al (2012) Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol 107(1):207–212
Easaw JC, Mason WP, Perry J et al (2011) Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme. Current oncology (Toronto, Ont.) 18(3):e126–e136
Olson JJ, Fadul CE, Brat DJ, Mukundan S, Ryken TC (2009) Management of newly diagnosed glioblastoma: guidelines development, value and application. J Neurooncol 93(1):1–23
Olson JJ, Ryken T (2008) Guidelines for the treatment of newly diagnosed glioblastoma: introduction. J Neurooncol 89(3):255–258
Narang J, Jain R, Arbab AS et al (2011) Differentiating treatment-induced necrosis from recurrent/progressive brain tumor using nonmodel-based semiquantitative indices derived from dynamic contrast-enhanced T1-weighted MR perfusion. Neuro Oncol 13(9):1037–1046
Jain R, Narang J, Sundgren PM et al (2010) Treatment induced necrosis versus recurrent/progressing brain tumor: going beyond the boundaries of conventional morphologic imaging. J Neurooncol 100(1):17–29
Alexiou GA, Tsiouris S, Kyritsis AP, Voulgaris S, Argyropoulou MI, Fotopoulos AD (2009) Glioma recurrence versus radiation necrosis: accuracy of current imaging modalities. J Neurooncol 95(1):1–11
Burger PC, Scheithauer BW, Lee RR, O’Neill BP (1997) An interdisciplinary approach to avoid the overtreatment of patients with central nervous system lesions. Cancer 80(11):2040–2046
Burger PC, Nelson JS, Boyko OB (1998) Diagnostic synergy in radiology and surgical neuropathology: neuroimaging techniques and general interpretive guidelines. Arch Pathol Lab Med 122(7):609–619
Burger PC, Nelson JS, Boyko OB (1998) Diagnostic synergy in radiology and surgical neuropathology: radiographic findings of specific pathologic entities. Arch Pathol Lab Med 122(7):620–632
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97(16):1180–1184
Riley RD, Ridley G, Williams K, Altman DG, Hayden J, de Vet HC (2007) Prognosis research: toward evidence-based results and a Cochrane methods group. J Clin Epidemiol 60(8):863–865; author reply 865–866
Altman DG, Riley RD (2005) Primer: an evidence-based approach to prognostic markers. Nat Clin Pract Oncol 2(9):466–472
Walters BC (1998) Clinical practice parameter development in neurosurgery. In: Bean J (ed) Neurosurgery in transition: the socioeconomic transformation of neurological surgery. Williams and Wilkins, Baltimore, pp 99–111
Lai R, Chu R, Fraumeni M, Thabane L (2006) Quality of randomized controlled trials reporting in the primary treatment of brain tumors. J Clin Oncol 24(7):1136–1144
Moher D, Schulz KF, Altman DG (2001) The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 357(9263):1191–1194
Bullock R, Chesnut RM, Clifton G et al (1996) Guidelines for the management of severe head injury. Brain Trauma Foundation. Eur J Emerg Med 3(2):109–127
Burger PC, Scheithauer BW (1994) Tumors of the central nervous system. Armed Forces Institute of Pathology, Washington
Burger PC, Scheithauer BW, Vogel FS (2002) Surgical pathology of the nervous system and its coverings, 4th edn. Churchill Livingstone, New York
Kleihues P, Cavenee WK (2000) Pathology and genetics of tumours of the nervous system. IARC Press, Lyon
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2007) WHO classification of tumours of the central nervous system, 4th edn. International Agency for Research, Lyon
Perry A, Brat DJ (2010) Practical surgical pathology: a diagnostic approach. Elsevier, Philadelphia
Brat DJ, Prayson RA, Ryken TC, Olson JJ (2008) Diagnosis of malignant glioma: role of neuropathology. J Neurooncol 89(3):287–311
Gupta M, Djalilvand A, Brat DJ (2005) Clarifying the diffuse gliomas: an update on the morphologic features and markers that discriminate oligodendroglioma from astrocytoma. Am J Clin Pathol 124(5):755–768
Miller CR, Dunham CP, Scheithauer BW, Perry A (2006) Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas. J Clin Oncol 24(34):5419–5426
Sheline GE, Wara WM, Smith V (1980) Therapeutic irradiation and brain injury. Int J Radiat Oncol Biol Phys 6(9):1215–1228
Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ (2008) Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9(5):453–461
Perry A, Schmidt RE (2006) Cancer therapy-associated CNS neuropathology: an update and review of the literature. Acta Neuropathol 111(3):197–212
Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996
Taal W, Brandsma D, de Bruin HG et al (2008) Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 113(2):405–410
Brandes AA, Franceschi E, Tosoni A et al (2008) MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26(13):2192–2197
de Wit MC, de Bruin HG, Eijkenboom W, Sillevis Smitt PA, van den Bent MJ (2004) Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 63(3):535–537
Chakravarti A, Erkkinen MG, Nestler U et al (2006) Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin Cancer Res Off J Am Assoc Cancer Res 12(15):4738–4746
Chamberlain MC, Glantz MJ, Chalmers L, Van Horn A, Sloan AE (2007) Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 82(1):81–83
Wong CS, Van der Kogel AJ (2004) Mechanisms of radiation injury to the central nervous system: implications for neuroprotection. Mol Interv 4(5):273–284
Brandes AA, Tosoni A, Spagnolli F et al (2008) Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. Neuro Oncol 10(3):361–367
Ruben JD, Dally M, Bailey M, Smith R, McLean CA, Fedele P (2006) Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys 65(2):499–508
Peterson K, Clark HB, Hall WA, Truwit CL (1995) Multifocal enhancing magnetic resonance imaging lesions following cranial irradiation. Ann Neurol 38(2):237–244
Brandes AA, Rigon A, Zampieri P et al (1998) Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme: a phase II study. Cancer 82(2):355–361
Glantz MJ, Choy H, Kearns CM et al (1996) Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas. J Clin Oncol 14(2):600–609
Levin VA, Yung WK, Bruner J et al (2002) Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas. Int J Radiat Oncol Biol Phys 53(1):58–66
Forsyth PA, Kelly PJ, Cascino TL et al (1995) Radiation necrosis or glioma recurrence: is computer-assisted stereotactic biopsy useful? J Neurosurg 82(3):436–444
Yoshii Y (2008) Pathological review of late cerebral radionecrosis. Brain Tumor Pathol 25(2):51–58
Burger PC, Mahley MS Jr, Dudka L, Vogel FS (1979) The morphologic effects of radiation administered therapeutically for intracranial gliomas: a postmortem study of 25 cases. Cancer 44(4):1256–1272
Schiffer D, Giordana MT, Paoletti P, Soffietti R, Tarenzi L (1980) Pathology of human malignant gliomas after radiation and chemotherapy. Acta Neurochir (Wien) 53(3–4):205–216
Schiffer D, Chio A, Giordana MT et al (1990) Vascular response to irradiation in malignant gliomas. J Neurooncol 8(1):73–84
Schiffer D, Giordana MT, Soffietti R, Sciolla R (1982) Histological observations on the regrowth of malignant gliomas after radiotherapy and chemotherapy. Acta Neuropathol 58(4):291–299
Burger PC, Nelson JS (1997) Stereotactic brain biopsies: specimen preparation and evaluation. Arch Pathol Lab Med 121(5):477–480
Burger PC, Vogel FS (1978) Frozen section interpretation in surgical neuropathology. II. Intraspinal lesions. Am J Surg Pathol 2(1):81–95
Burger PC (1985) Use of cytological preparations in the frozen section diagnosis of central nervous system neoplasia. Am J Surg Pathol 9(5):344–354
Ironside JW (1994) Update on central nervous system cytopathology. II. Brain smear technique. J Clin Pathol 47(8):683–688
Burger PC, Shibata T, Kleihues P (1986) The use of the monoclonal antibody Ki-67 in the identification of proliferating cells: application to surgical neuropathology. Am J Surg Pathol 10(9):611–617
Prayson RA (2002) Cell proliferation and tumors of the central nervous system, part II: radiolabeling, cytometric, and immunohistochemical techniques. J Neuropathol Exp Neurol 61(8):663–672
Daumas-Duport C, Scheithauer B, O’Fallon J, Kelly P (1988) Grading of astrocytomas. A simple and reproducible method. Cancer 62(10):2152–2165
Brat DJ, Parisi JE, Kleinschmidt-DeMasters BK et al (2008) Surgical neuropathology update: a review of changes introduced by the WHO classification of tumours of the central nervous system, 4th edition. Arch Pathol Lab Med 132(6):993–1007
Colodner KJ, Montana RA, Anthony DC, Folkerth RD, De Girolami U, Feany MB (2005) Proliferative potential of human astrocytes. J Neuropathol Exp Neurol 64(2):163–169
Giannini C, Scheithauer BW, Burger PC et al (1999) Cellular proliferation in pilocytic and diffuse astrocytomas. J Neuropathol Exp Neurol 58(1):46–53
Deininger MH, Grote E, Wickboldt J, Meyermann R (2000) Distinct radiochemotherapy protocols differentially influence cellular proliferation and expression of p53 and Bcl-2 in glioblastoma multiforme relapses in vivo. J Neurooncol 48(2):121–129
Riemenschneider MJ, Jeuken JW, Wesseling P, Reifenberger G (2010) Molecular diagnostics of gliomas: state of the art. Acta Neuropathol 120(5):567–584
Hunter SB, Brat DJ, Olson JJ, Von Deimling A, Zhou W, Van Meir EG (2003) Alterations in molecular pathways of diffusely infiltrating glial neoplasms: application to tumor classification and anti-tumor therapy (Review). Int J Oncol 23(4):857–869
Ohgaki H, Kleihues P (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64(6):479–489
Collins VP (2007) Mechanisms of disease: genetic predictors of response to treatment in brain tumors. Nat Clin Pract Oncol 4(6):362–374
Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360(8):765–773
Aldape K, Burger PC, Perry A (2007) Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. Arch Pathol Lab Med 131(2):242–251
Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP (1994) Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 145(5):1175–1190
Perry A, Fuller CE, Banerjee R, Brat DJ, Scheithauer BW (2003) Ancillary FISH analysis for 1p and 19q status: preliminary observations in 287 gliomas and oligodendroglioma mimics. Front Biosci 8:a1–a9
McDonald JM, See SJ, Tremont IW et al (2005) The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer 104(7):1468–1477
Burger PC, Minn AY, Smith JS et al (2001) Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections. Mod Pathol 14(9):842–853
Ueki K, Nishikawa R, Nakazato Y et al (2002) Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. Clinical Cancer Res Off J Am Assoc Cancer Res 8(1):196–201
Nigro JM, Takahashi MA, Ginzinger DG et al (2001) Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. Am J Pathol 158(4):1253–1262
Louis DN (1994) The p53 gene and protein in human brain tumors. J Neuropathol Exp Neurol 53:11–21
Yaziji H, Massarani-Wafai R, Gujrati M, Kuhns JG, Martin AW, Parker JC Jr (1996) Role of p53 immunohistochemistry in differentiating reactive gliosis from malignant astrocytic lesions. Am J Surg Pathol 20(9):1086–1090
Kurtkaya-Yapicier O, Scheithauer BW, Hebrink D, James CD (2002) p53 in nonneoplastic central nervous system lesions: an immunohistochemical and genetic sequencing study. Neurosurgery 51(5):1246–1254; discussion 1254–1255
Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51(23 Pt 1):6304–6311
Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB (1992) Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89(16):7491–7495
Murphy M, Mabruk MJ, Lenane P et al (2002) Comparison of the expression of p53, p21, Bax and the induction of apoptosis between patients with basal cell carcinoma and normal controls in response to ultraviolet irradiation. J Clin Pathol 55(11):829–833
Murphy M, Mabruk MJ, Lenane P et al (2002) The expression of p53, p21, Bax and induction of apoptosis in normal volunteers in response to different doses of ultraviolet radiation. Br J Dermatol 147(1):110–117
Caspari T (2000) How to activate p53. Curr Biol 10(8):R315–R317
Schittenhelm J, Mittelbronn M, Nguyen TD, Meyermann R, Beschorner R (2008) WT1 expression distinguishes astrocytic tumor cells from normal and reactive astrocytes. Brain Pathol 18(3):344–353
Capper D, Sahm F, Hartmann C, Meyermann R, von Deimling A, Schittenhelm J (2010) Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes. Am J Surg Pathol 34(8):1199–1204
Parsons MJ, Patel P, Brat DJ, Colbert L, Vertino PM (2009) Silencing of TMS1/ASC promotes resistance to anoikis in breast epithelial cells. Cancer Res 69(5):1706–1711
Capper D, Weissert S, Balss J et al (2010) Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20(1):245–254
Horbinski C, Kofler J, Kelly LM, Murdoch GH, Nikiforova MN (2009) Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues. J Neuropathol Exp Neurol 68(12):1319–1325
Camelo-Piragua S, Jansen M, Ganguly A, Kim JC, Louis DN, Nutt CL (2010) Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis. Acta Neuropathol 119(4):509–511
Watanabe T, Nobusawa S, Kleihues P, Ohgaki H (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174(4):1149–1153
Smith JS, Tachibana I, Passe SM et al (2001) PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93(16):1246–1256
Liu L, Backlund LM, Nilsson BR et al (2005) Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas. J Mol Med 83(11):917–926
Frederick L, Wang XY, Eley G, James CD (2000) Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60(5):1383–1387
Wong AJ, Ruppert JM, Bigner SH et al (1992) Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 89(7):2965–2969
Wessels PH, Twijnstra A, Kessels AG et al (2002) Gain of chromosome 7, as detected by in situ hybridization, strongly correlates with shorter survival in astrocytoma grade 2. Genes Chromosomes Cancer 33(3):279–284
Okada Y, Ohno C, Ueki K, Ogino M, Kawamoto S, Kim P (2007) Comparison of numerical change of epidermal growth factor receptor gene among pre- and postradiation glioma, and gliosis, and its clinical use. Brain Tumor Pathol 24(1):15–18
Burel-Vandenbos F, Benchetrit M, Miquel C et al (2011) EGFR immunolabeling pattern may discriminate low-grade gliomas from gliosis. J Neurooncol 102(2):171–178
Camelo-Piragua S, Jansen M, Ganguly A et al (2011) A sensitive and specific diagnostic panel to distinguish diffuse astrocytoma from astrocytosis: chromosome 7 gain with mutant isocitrate dehydrogenase 1 and p53. J Neuropathol Exp Neurol 70(2):110–115
Verhaak RG, Hoadley KA, Purdom E et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17(1):98–110
Cooper LA, Gutman DA, Chisolm C et al (2012) The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma. Am J Pathol 180(5):2108–2119
Cooper LA, Gutman DA, Long Q et al (2010) The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas. PLoS ONE 5(9):e12548
Parsons DW, Jones S, Zhang X et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science (New York, N.Y.) 321(5897):1807–1812
Noushmehr H, Weisenberger DJ, Diefes K et al (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17(5):510–522
Kloosterhof NK, Bralten LB, Dubbink HJ, French PJ, van den Bent MJ (2011) Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma? Lancet Oncol 12(1):83–91
Capper D, Reuss D, Schittenhelm J et al (2011) Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. Acta Neuropathol 121(2):241–252
Acknowledgments
We would like to acknowledge the AANS/CNS Joint Guidelines Committee for their review, comments and suggestions, the contributions of Laura Mitchell, CNS Guidelines Manager for organizational assistance, Maxine Brown for searching for and retrieving literature and Amy Allison for reference library consultations. We would also like to acknowledge the following individual JGC members for their contributions throughout the review process: Sepideh Amin-Hanjani, MD, FAANS, FACS, FAHA, Martina Stippler, MD, Alexander Khalessi, MD, Isabelle Germano, MD, Sean D. Christie, MD, FRCS (C), Gregory J. Zipfel, MD, Zachary Litvack, MD, MCR, Ann Marie Flannery, MD, Patricia B Raksin, MD, Joshua M. Rosenow, MD, FACS, Steven Casha, MD, PhD, Julie G. Pilitsis, MD, PhD, Gabriel Zada, MD, Adair Prall, Krystal Tomei, MD, Gregory W Hawryluk, MD.
Conflict of interest
Task Force members report potential COIs prior to beginning work on the guideline and at the time of publication. COI disclosures are reviewed by the Task Force Chair and taken into consideration when determining writing assignments. Resolution of potential COIs included Task Force members were assigned to chapters that did not involve or in any way relate to the potential COIs disclosed.
Disclaimer of liability
The information in these guidelines reflects the current state of knowledge at the time of completion. The presentations are designed to provide an accurate review of the subject matter covered. These guidelines are disseminated with the understanding that the recommendations by the authors and consultants who have collaborated in their development are not meant to replace the individualized care and treatment advice from a patient’s physician(s). If medical advice or assistance is required, the services of a physician should be sought. The proposals contained in these guidelines may not be suitable for use in all circumstances. The choice to implement any particular recommendation contained in these guidelines must be made by a managing physician in light of the situation in each particular patient and on the basis of existing resources.
Funding Source
These guidelines were funded exclusively by the CNS and Tumor Section of the American Association of Neurological Surgeons and the Congress of Neurological Surgeons whom received no funding from outside commercial sources to support the development of this document unless otherwise stated in this section.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Brat, D.J., Ryken, T.C., Kalkanis, S.N. et al. The role of neuropathology in the management of progressive glioblastoma. J Neurooncol 118, 461–478 (2014). https://doi.org/10.1007/s11060-013-1331-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-013-1331-z